Bendamustine hydrochloride - CAS 3543-75-7
Catalog number: 3543-75-7
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Bendamustine hydrochloride is the hydrochloride salt of bendamustine, a bifunctional mechlorethamine derivative with alkylator and antimetabolite activities. Bendamustine possesses three active moieties: an alkylating group; a benzimidazole ring, which may act as a purine analogue; and a butyric acid side chain. Although its exact mechanism of action is unknown, this agent appears to act primarily as an alkylator. Bendamustine metabolites alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis. Bendamustine may differ from other alkylators in that it may be more potent in activating p53-dependent stress pathways and inducing apoptosis; it may induce mitotic catastrophe; and it may activate a base excision DNA repair pathway rather than an alkyltransferase DNA repair mechanism.
Publictions citing BOC Sciences Products
  • >> More
SDX-105 (Cytostasane) HCl
1.Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.
Laurenti L1, Innocenti I2, Autore F2, Vannata B3, Efremov DG4, Ciolli S5, Del Poeta G6, Mauro FR7, Cortelezzi A8, Borza PA9, Ghio F10, Mondello P11, Murru R12, Gozzetti A13, Cariccio MR14, Piccirillo N2, Boncompagni R5, Cantonetti M6, Principe MI6, Reda G Leuk Res. 2015 Oct;39(10):1066-70. doi: 10.1016/j.leukres.2015.07.009. Epub 2015 Jul 26.
The front-line therapy for CLL young and fit patients is chemo-immunotherapy with fludarabine-cyclophosphamide-rituximab (FCR). FCR regimen results in a significant myelosuppression and high rates of early and late infections especially in elderly patients. German CLL study group compared FCR vs. bendamustine-rituximab (BR) in fit untreated patients. The response rates with BR or FCR were comparable, BR could be an alternative 1st-line treatment for elderly patients. Here we report retrospective data of 70 elderly (≥65 years) CLL patients from 12 Italian centers treated with BR as front-line therapy. The primary end points were overall response rate (complete remission/partial remission) and safety. Forty-seven males and 23 females, with a median age of 72 years, were included in the study. Eight patients were unfit for CIRS. The OR rate was 88.6% (31.4% CR and 57.2% PR). Progression free survival, treatment free survival and overall survival rates at 2-years were 79%, 90.
2.Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Allendorf DJ1, Bordoni RE2, Grant SC3, Saleh MN4, Reddy VB5, Jerome ML6, Dixon PM7, Miley DK6, Singh KP8, Robert F9. Cancer Chemother Pharmacol. 2015 Nov;76(5):949-55. doi: 10.1007/s00280-015-2869-6. Epub 2015 Sep 22.
PURPOSE: The sequence bendamustine (B) + Irinotecan (I) followed by etoposide (E) + carboplatin (C) was hypothesized to increase progression-free survival (PFS) and overall survival (OS) in untreated extensive-disease small cell lung cancer (EDSCLC) patients compared to historical controls by exploiting mitotic catastrophe. Absent expression of ERCC-1 and expression of topoisomerases were hypothesized to be predictive for PFS and OS.
3.Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
Czuczman MS1, Goy A2, Lamonica D3, Graf DA3,4, Munteanu MC5, van der Jagt RH6. Ann Hematol. 2015 Dec;94(12):2025-32. doi: 10.1007/s00277-015-2478-9. Epub 2015 Sep 28.
In most cases of relapsed/refractory mantle cell lymphoma (MCL), patients respond to salvage therapy, though typically responses are partial and/or transient followed by disease progression, even with newer agents (e.g., ibrutinib). In this multicenter, open-label, single-arm, phase II study, patients with relapsed/refractory non-blastoid MCL received bendamustine 90 mg/m(2) (days 1 and 2) and rituximab 375 mg/m(2) (day 1) for 6 planned 28-day cycles. Functional imaging with 18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) was conducted at baseline and after cycle 6. Forty-five patients were enrolled (median age, 70 years; 82 % stage IV disease; median number of prior chemotherapies, 2 [range, 1-4]), showing an overall response rate (ORR; primary efficacy measure) of 82 % (complete response [CR], 40 %; partial response, 42 %). In the 32 patients with complete 18F-FDG PET/CT data, 75 % achieved a complete metabolic response.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

CAS 127-65-1 Chloramine-T

(CAS: 127-65-1)

Chloramine-T could be commonly used as decolorizer, sanitizer and detergent in sorts of chemical areas.

CAS 347323-96-0 ITX3

(CAS: 347323-96-0)

ITX3 is a specific inhibitor of endogenous TrioN activity acting on the GEF domain and selective cell active inhibitor of the Trio/RhoG/Rac1 pathway. The compou...

CAS 248281-84-7 Laquinimod

(CAS: 248281-84-7)

Laquinimod, also known as,  is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple ...

CAS 504-03-0 Nanofin

(CAS: 504-03-0)

Nanofin is neuropathic blocker used for mild to moderate hypertension.

CAS 119348-12-8 5α-reductase-IN-1

(CAS: 119348-12-8)

An inhibitor of 5α-reductase

(CAS: 171655-92-8)

NS-2214, an azabicyclo compound, has been found to be a dopamine uptake inhibitor that was once studied in the treatment of Parkinson's disease.

CAS 213400-34-1 UPF-648

(CAS: 213400-34-1)

Potent and selective inhibitor of kynurenine-3-monooxygenase (KMO, or kynurenine hydroxylase) activity (IC50: 20 nM); Active (+)-(1S,2S)-enantiomer; Useful tool...

CAS 3992-42-5 2'-Deoxycytidine hydrochloride

2'-Deoxycytidine hydrochloride
(CAS: 3992-42-5)

2'-Deoxyguanosine HCl is composed of the purine nucleoside guanine linked by its N9 nitrogen to the C1 carbon of deoxyribose.

GSK-2262167 sodium
(CAS: 458576-13-0)

GSK-2262167 is a potent S1P3-sparing and S1P1 agonist and has a potent activity is in a collagen-induced arthritis model as efficacious as fingolimod and show...

CAS 70052-12-9 Eflornithine

(CAS: 70052-12-9)

Eflornithine is a difluoromethylated ornithine compound with antineoplastic activity. Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme requ...

CAS 1955550-51-2 FMK 9a

FMK 9a
(CAS: 1955550-51-2)

FMK 9a is a covalent autophagin-1 inhibitor (IC50= 80 and 73 μM in FRET and LRA assay).

Monohydroxy Netupitant
(CAS: 910808-12-7)

Monohydroxy Netupitant is the metabolite of Netupitant which is a potent and selective neurokinin-1 receptor (NK1) receptor antagonist. It is achiral and orally...

CAS 105816-04-4 Nateglinide

(CAS: 105816-04-4)

Nateglinide(Starlix) is an insulin secretagog agent that lowers blood glucose levels by stimulating insulin secretion from the pancreas. It achieves this by clo...

CAS 107534-93-0 Macelignan

(CAS: 107534-93-0)

Macelignan is a natural compound isolated from Myristica fragrans Houtt. It possesses therapeutic potentials against neurodegenerative diseases with oxidative s...

(CAS: 1375751-08-8)

BMS-955829 shows excellent Metabotropic glutamate receptor 5 (mGluR5) binding affinity, low glutamate fold shift, and high selectivity for the mGluR5 subtype. B...

CAS 50-01-1 Guanidine Hydrochloride

Guanidine Hydrochloride
(CAS: 50-01-1)

Guanidine HCl, the crystalline compound of strong alkalinity formed by the oxidation of guanine, is a normal product of protein metabolism and a protein denatur...

(CAS: 92478-27-8)

Morinidazole is a novel 5-nitroimidazole antimicrobial drug. It undergoes extensive metabolism in humans via N+-glucuronidation and sulfation. It is used for th...

CAS 6020-18-4 Coptisine chloride

Coptisine chloride
(CAS: 6020-18-4)

Coptisine chloride, an alkaloid found in Chinese goldthread, can be absorbed across intestinal epithelial cells, and they are completely absorbed compounds.

CAS 148554-65-8 seco Rapamycin Sodium Salt

seco Rapamycin Sodium Salt
(CAS: 148554-65-8)

Seco-rapamycin is the first in vivo open-ring metabolite of rapamycin which is a natural macrolide immunosuppressant. Seco-rapamycin inhibits the ChT-L (D) and ...

(CAS: 1253186-56-9)

This active molecular is a calcium release-activated calcium modulator (ORAI1) inhibitor. GSK-7975A inhibited toxin-induced activation of ORAI1 and/or activatio...

Chemical Structure

CAS 3543-75-7 Bendamustine hydrochloride

Quick Inquiry

Verification code

Featured Items